

Title (en)  
C5A RECEPTOR ANTAGONISTS

Title (de)  
C5A-REZEPTORANTAGONISTEN

Title (fr)  
ANTAGONISTES DU RECEPTEUR C5A

Publication  
**EP 1838725 A1 20071003 (EN)**

Application  
**EP 06706265 A 20060117**

Priority  
• EP 2006000365 W 20060117  
• EP 05000857 A 20050117  
• EP 06706265 A 20060117

Abstract (en)  
[origin: WO2006074964A1] The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure: (I), whereby X1 is a radical having a mass of about 1-300, whereby X1 is preferably selected from the group comprising R5-, R5-CO-, R5-N(R6)-CO-, R5-O-CO-, R5-SO<SUB>2</SUB>-, R5-N(R6)-SO<SUB>2</SUB>-, R5-N(R6)-, R5-N(R6)-CS-, R5-N(R6)-C(NH)-, R5-CS-, R5-P(O)OH-5 R5-B(OH)-, and R5-CH=N-O-CH<SUB>2</SUB>-CO-, whereby R5 and R6 are individually and independently selected from the group comprising H, F, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, alkoxy, alkoxyalkyl, substituted alkoxyalkyl, aryloxyalkyl and substituted aryloxyalkyl, X2 is a radical that mimics the biological binding characteristics of a phenylalanine unit, X3 and X4 are individually and independently a spacer, whereby the spacer is preferably selected from the group comprising amino acids, amino acid analogs and amino acid derivatives, X5 is a radical that mimics the biological binding characteristics of a cyclohexylalanine or homoleucine unit, X6 is a radical that mimics the biological binding characteristics of a tryptophane unit, X7 is a radical that mimics the biological binding characteristics of a norleucine or phenylalanine unit, a chemical bond X3 and X7 is formed, and the connecting lines - in formula (I) indicate chemical bonds, whereby the chemical bond is individually and independently selected from the group comprising covalent bonds, ionic bonds and coordinative bonds, whereby preferably the bond is a chemical bond and more preferably the chemical bond is a bond selected from the group comprising amide bonds, disulfide bonds, ether bonds, thioether bonds, oxime bonds and aminotriazine bonds, whereby the compound is in particular useful for the manufacture of a medicament for the treatment of autoimmune diseases.

IPC 8 full level  
**C07K 7/06** (2006.01); **C07K 7/56** (2006.01); **C07K 7/64** (2006.01); **C07K 14/47** (2006.01); **C07K 14/705** (2006.01)

CPC (source: EP KR US)  
**A61P 1/04** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 17/14** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 27/16** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 7/06** (2013.01 - EP KR US); **C07K 7/56** (2013.01 - EP US); **C07K 7/64** (2013.01 - EP KR US); **C07K 14/47** (2013.01 - KR); **C07K 14/472** (2013.01 - EP US); **C07K 14/705** (2013.01 - KR)

Citation (search report)  
See references of WO 2006074964A1

Citation (examination)  
• WO 03033528 A1 20030424 - UNIV QUEENSLAND [AU], et al  
• WO 9009162 A2 19900823 - ABBOTT LAB [US]  
• WO 9221361 A1 19921210 - ABBOTT LAB [US]  
• MORGAN B P ET AL: "Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 138, 1 January 2004 (2004-01-01), pages 430 - 438, XP007908350, ISSN: 0009-9104, DOI: DOI:10.1111/J.1365-2249.2004.02646.X  
• VERGUNST C E ET AL: "Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 46, 27 October 2007 (2007-10-27), pages 1773 - 1778, XP007908349, ISSN: 1462-0324, DOI: DOI:10.1093/RHEUMATOLOGY/KEM222  
• MARCH D.R. ET AL.: "Potent cyclic antagonists of the complement C5A receptor on human polymorphonuclear leukocytes. Relationships between structures and activity", MOLECULAR PHARMACOLOGY, vol. 65, no. 4, 1 April 2005 (2005-04-01), pages 868 - 879, XP001205138

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)  
AL BA HR MK YU

DOCDB simple family (publication)  
**WO 2006074964 A1 20060720**; AU 2006205830 A1 20060720; BR PI0606647 A2 20090714; CA 2594934 A1 20060720; CN 101107264 A 20080116; EP 1838725 A1 20071003; IL 184278 A0 20071031; JP 2008526915 A 20080724; KR 20070104355 A 20071025; MX 2007008640 A 20070912; RU 2007131267 A 20090227; SG 158191 A1 20100129; US 2008161232 A1 20080703; ZA 200705237 B 20090624

DOCDB simple family (application)  
**EP 2006000365 W 20060117**; AU 2006205830 A 20060117; BR PI0606647 A 20060117; CA 2594934 A 20060117; CN 200680002512 A 20060117; EP 06706265 A 20060117; IL 18427807 A 20070628; JP 2007550769 A 20060117; KR 20077016266 A 20070716; MX 2007008640 A 20060117; RU 2007131267 A 20060117; SG 2009087370 A 20060117; US 81405006 A 20060117; ZA 200705237 A 20070702